Related Experiment Video
Updated: Sep 18, 2025
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
G0S2: a potential target for NSCLC identified through prognostic models from multi-Omic analysis of regulatory T cell
Min Zhou1,2, Mengqing Liu1, Yile Hu3
1Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.
Abstract:
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, with immunotherapy proving effective only in a subset of patients, highlighting the urgent need for improved biomarkers and therapeutic targets. This study explored regulatory T cell (Treg) metabolism-related genes in NSCLC and established a seven-gene prognostic signature (TIMP1, BIRC3, G0S2, PRKCB, PDE4B, CD52, and ACP5) through multi-omics analysis. The model stratified patients into high- and low-risk groups exhibiting distinct immune profiles and drug sensitivities. Clinical validation confirmed that elevated BIRC3 and G0S2 expression correlated with poorer prognosis, while functional assays demonstrated that G0S2 inhibition suppressed tumour progression and reduced Treg infiltration in vivo. These findings position G0S2 as a promising biomarker for immunotherapy response and a potential therapeutic target, providing insights into Treg-mediated immune regulation and advancing personalized NSCLC treatment strategies.
Insights
This study identified seven regulatory T cell metabolism genes to predict non-small cell lung cancer (NSCLC) patient outcomes. G0S2 inhibition suppressed tumor growth and T cell infiltration, suggesting it as a therapeutic target for NSCLC.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Non-small cell lung cancer (NSCLC) is a major cause of cancer mortality.
- Immunotherapy efficacy in NSCLC is limited to a subset of patients.
- Improved biomarkers and therapeutic targets are urgently needed for NSCLC.
Purpose of the Study:
- To investigate regulatory T cell (Treg) metabolism-related genes in NSCLC.
- To develop a prognostic signature for NSCLC based on these genes.
- To evaluate the potential of identified genes as therapeutic targets and biomarkers.
Main Methods:
- Multi-omics analysis was used to identify key genes.
- A seven-gene prognostic signature (TIMP1, BIRC3, G0S2, PRKCB, PDE4B, CD52, ACP5) was established.
- In vivo functional assays were performed to assess the role of G0S2.
Main Results:
- A seven-gene signature stratified NSCLC patients into high- and low-risk groups with distinct immune profiles and drug sensitivities.
- Elevated BIRC3 and G0S2 expression correlated with poorer prognosis in NSCLC.
- Inhibition of G0S2 suppressed tumor progression and reduced Treg infiltration in vivo.
Conclusions:
- The seven-gene signature provides a novel prognostic tool for NSCLC.
- G0S2 is identified as a potential biomarker for immunotherapy response in NSCLC.
- G0S2 inhibition represents a promising therapeutic strategy for NSCLC treatment.
